A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
NCT01402986
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
689
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
OTHER:
Placebo Q2W
BIOLOGICAL:
Tralokinumab 300 mg, Q2W
OTHER:
Placebo, Q2/4W
BIOLOGICAL:
Tralokinumab 300 mg, Q2/4W
Sponsor
MedImmune LLC